2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108688
    GSK2033 1221277-90-2 99.37%
    GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
    GSK2033
  • HY-107420
    AY 9944 366-93-8 ≥99.0%
    AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC50 of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol.
    AY 9944
  • HY-112829
    Denifanstat 1399177-37-7 99.58%
    Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.
    Denifanstat
  • HY-101140
    KI696 1799974-70-1 ≥98.0%
    KI696 is a high affinity probe that disrupts the Keap1/NRF2 interaction. KI696 is a potent and selective inhibitor of the KEAP1/NRF2 interaction.
    KI696
  • HY-13867
    Bisindolylmaleimide I 133052-90-1 98.15%
    Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor.
    Bisindolylmaleimide I
  • HY-16107
    BMS-303141 943962-47-8 99.02%
    BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
    BMS-303141
  • HY-128851
    Coenzyme A 85-61-0
    Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
    Coenzyme A
  • HY-W010388
    Creatine 57-00-1 ≥98.0%
    Creatine, an endogenous amino acid derivative, plays an important role in cellular energy, especially in muscle and brain.
    Creatine
  • HY-44134
    Dimethyl 2-oxoglutarate 13192-04-6
    Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate), a cell permeable 2-oxoglutarate derivative, is a tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate serves as a crucial intermediate in the Krebs cycle and an essential nitrogen carrier in metabolic pathways during biological processes. Dimethyl 2-oxoglutarate inhibits autophagy in an IDH1-, IDH2- and ACLY-dependent fashion in cultured human cells. Dimethyl 2-oxoglutarate efficiently prevents autophagy induced by starvation in mice.
    Dimethyl 2-oxoglutarate
  • HY-150012
    N-Lactoyl-Phenylalanine 183241-73-8
    N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance.
    N-Lactoyl-Phenylalanine
  • HY-B0089
    Acarbose 56180-94-0 ≥98.0%
    Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.
    Acarbose
  • HY-N0390S1
    L-Glutamine-13C5 184161-19-1 ≥98.0%
    L-Glutamine-13C5 is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
    L-Glutamine-13C5
  • HY-W010452
    3-Hydroxybutyric acid sodium 150-83-4 ≥98.0%
    3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids.
    3-Hydroxybutyric acid sodium
  • HY-15848
    AdipoRon 924416-43-3
    AdipoRon is an orally active adiponectin receptor (AdipoR) agonist, binding to AdipoR1 and AdipoR2 with Kds of 1.8 and 3.1 μM, respectively.
    AdipoRon
  • HY-103173
    5'-N-Ethylcarboxamidoadenosine 35920-39-9 ≥99.0%
    5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.
    5'-N-Ethylcarboxamidoadenosine
  • HY-B0345A
    ATP disodium salt 987-65-5 ≥98.0%
    ATP disodium salt (Adenosine 5'-triphosphate disodium salt) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt is an important endogenous signaling molecule in immunity and inflammation.
    ATP disodium salt
  • HY-B2163
    Astaxanthin 472-61-7 ≥98.0%
    Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed.
    Astaxanthin
  • HY-148189
    Aldometanib 2904601-67-6 99.37%
    Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis.
    Aldometanib
  • HY-108529
    BMS493 215030-90-3 99.94%
    BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 increases nuclear corepressor interaction with RARs. BMS493 also could prevent retinoic acid-induced differentiation. BMS493 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BMS493
  • HY-P0055
    GLP-1(7-37) 106612-94-6 99.89%
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37)
Cat. No. Product Name / Synonyms Application Reactivity